NuProbe Global, a genomics and molecular diagnostics technology company leading in ultra-high sensitivity tumor gene testing and genetic testing for infertility, announced the clsoing of $50 million in its Series B financing round.  

The round was jointly led by AstraZeneca-CICC Medical Industry Fund, China Resources-CP Group Life Science Fund, and existing shareholder Panlin Capital. Also participating were Hao Lan Capital, Shanghai Deguan Asset Management Co., Ltd., and Pappas Capital as well as several existing shareholders including BioTrack Capital, Sequoia China, Yonghua Capital, and TuoBang Capital. 

CEC Capital served as the exclusive financial advisor to NuProbe Global in this transaction.

The proceeds from this financing will be utilized to further advance NuProbe Global's leading nucleic acid testing underlying technology, accelerate the development of new genetic testing products, expand its commercial teams in both the United States and China, and continue to drive the registration and approval of multiple clinical products.